Pharmaron Beijing (300759.SZ)

Executive Summary

Pharmaron Beijing Co., Ltd. (300759.SZ) is a leading global contract research, development, and manufacturing organization (CRDMO) headquartered in Beijing, China. The company provides integrated R&D and production services spanning the entire drug development lifecycle, from early discovery to commercial manufacturing, for small molecules, biologics, cell and gene therapies, and oligonucleotides. With operational facilities across China, the U.S., and the U.K., Pharmaron serves a diverse international client base. The company has benefited from the global trend of pharmaceutical outsourcing and China's growing biotech ecosystem. Financially, Pharmaron has demonstrated robust revenue growth driven by its comprehensive service offerings and strong client retention. However, it faces challenges from geopolitical tensions, intensified competition in the CDMO space, and a volatile biotech funding environment. Valuation remains high at ~$54 billion estimated market cap, reflecting its strategic position. We maintain a cautiously positive outlook given its integrated model and expansion plans.

Upcoming Catalysts (preview)

• TBDMajor multi-year contract wins with global pharma or biotech80% success
• H2 2026Completion or announcement of new capacity expansion (e.g., U.S. or U.K. facilities)70% success
• Q3 2026Inclusion in major Chinese or global equity index, boosting investor visibility60% success